Background: The aim of this study was to detect cysteinyl leukotriene (Cys-LT) receptors in aspirin-sensitive nasal polyposis patients, and compare them with nasal polyposis and chronic rhinosinusitis patients without aspirin sensitivity. Methods: The formalin-fixed, paraffin-embedded tissue blocks of a total of 52 patients undergoing endoscopic sinus surgery were reviewed by an experienced head and neck pathologist. Of these 52 cases, there were 22 nasal polyposis cases with aspirin sensitivity, 15 nasal polyposis cases without aspirin sensitivity and 15 chronic rhinosinusitis cases without aspirin sensitivity. Immunohistochemical analyses for Cys-LT1 receptors were performed with polyclonal rabbit antibody. Results: Eosinophil receptor intensity levels were 27.68, 21.67, and 14.40, respectively. This was statistically insignificant (p <0.089). Mast cell receptor intensity levels were 8.41, 5.27, and 4.27, respectively. In the aspirin-sensitive group, mast cell receptor intensity was significantly higher when compared to the nasal polyposis and chronic rhinosinusitis group (p < 0.0001 and p < 0.0001, respectively). The difference in Cys-LT1 receptor immunoreactivity in both eosinophils and mast cells among the 3 groups was also found to be statistically significant (p < 0.001). Conclusions: Our study revealed that nasal polyps of aspirin-sensitive patients were infiltrated with eosinophils and mast cells, Cys-LT1 receptor proportions in these inflammatory cells were found to be higher and Cys-LT1 receptor immunoreactivity in eosinophils and mast cells was increased.

Keywords:
Aspirin sensitivity, Nasal polyposis, Leukotriene receptors
This content is only available via PDF.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.